Sweden’s BioArctic: A Potential Paradigm Shift in Alzheimer’s Treatment?
Swedish biotech BioArctic, in collaboration with Japanese firm Eisai, has seen positive Phase IIb results for its BAN2401 antibody – potentially the first disease-modifying treatment for Alzheimer’s Disease and the…